Servier $210m bet on IDEAYA’s uveal melanoma therapy darovasertib seems to have paid off, as a trial sets up regulatory filings later in 2026.

An AI tool could identify colorectal cancer patients most likely to respond to bevacizumab, which was recently backed for NHS use.

Revolution Medicines reported Monday that its experimental KRAS inhibitor called daraxonrasib succeeded in a registrational trial for pancreatic cancer. And now, the company plans to

AstraZeneca’s hyperkalaemia drug Lokelma could see its use by the NHS more than double thanks to updated guidance from NICE.

Ideaya’s late-stage data for a rare eye cancer drug has passed the company’s benchmark for success, bolstering expectations for a planned accelerated filing in the